MDXG FINANCIAL STATEMENTS

MiMedx Group Inc — balance sheet, income statement and cash flow trends

MDXGMiMedx Group Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue389.4 M $+10.5%

Gross Profit315.6 M $+9.4%

Operating Income39.6 M $-26.6%

EBITDA57.3 M $-9.7%

Net Income30.7 M $-23.6%

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
MDXG	10.5%	81.0%	14.7%	7.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
MDXG	10.5%	81.0%	14.7%	7.9%
OMER	—	—	—	—
ZURA	-100.0%	—	—	—
DNA	-40.5%	75.0%	-149.2%	-215.4%
ARVN	-79.1%	97.4%	-242.2%	-247.5%
PRTA	-58.0%	46.8%	-129.0%	-260.9%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity242.9 M $79%
Current Liabilities44.6 M $14%
Long-term Liabilities21.2 M $7%

Key Figures

YoY change

Total Assets308.7 M $+14.1%

Total Liabilities65.7 M $-2.8%

Total Equity242.9 M $+19.8%

Cash & ST Investments159.8 M $+50.1%

Total Debt17.6 M $-5.7%

Net Debt-142.2 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
MDXG	5.39	7.2%	-2.48	78.7%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
MDXG	5.39	7.2%	-2.48	78.7%
OMER	3.03	-490.5%	—	-22.1%
ZURA	19.33	—	—	94.9%
DNA	5.15	92.7%	-0.18	42.9%
ARVN	5.44	2.2%	2.80	59.7%
PRTA	10.43	2.4%	4.31	89.3%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow70.6 M $+7.7%

Capital Expenditures5.1 M $-19.1%

Free Cash Flow65.5 M $+10.6%

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
MDXG	18.1%	16.8%	1.3%	229.9%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
MDXG	18.1%	16.8%	1.3%	229.9%
OMER	—	—	—	—
ZURA	—	—	—	96.3%
DNA	-117.5%	-129.7%	17.7%	54.5%
ARVN	-284.2%	-287.4%	3.1%	114.8%
PRTA	-140.4%	-140.6%	0.2%	53.8%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on MDXG

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.